Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Johnson & Johnson Tops 2Q Forecasts Despite Profit Drop

By LINDA A. JOHNSON , AP Medical Writer | July 20, 2016

Surging second-quarter sales of Johnson & Johnson’s prescription drugs, its healthiest business, were more than offset by a one-time gain a year ago, driving profit down 11.5 percent.

But the health care giant easily beat Wall Street’s expectations and raised its full-year financial forecasts. Its shares rose to an all-time high Tuesday.

Sales of several key new medicines buoyed revenue, and medical device sales edged up. But sales dipped for consumer products such as Band-Aids and Johnson’s Baby Powder. More importantly, J&J’s top-selling prescription drug is facing cheaper competition, possibly as soon as this year, depending on the outcome of litigation.

Remicade, an injected biologic drug for immune disorders including rheumatoid arthritis, already has competition in some other countries from “biosimilar” versions, near-copies of complex biologic drugs manufactured in living cells. Higher U.S. sales offset an overseas decline and boosted total Remicade sales to nearly $1.8 billion in the second quarter. As biosimilars reach the market in the U.S. and additional countries, total sales are expected to fall.

The world’s biggest maker of health care products reported net income of $4 billion, or $1.43 per share. That was down from $4.52 billion, or $1.61 per share, a year ago when the company had a $931 million gain from the sale of rights to pain drug Nucynta. J&J also took a $557 million charge for litigation costs in the latest quarter.

Adjusted for one-time items, earnings came to $1.74 per share, 7 cents more than analysts expected.

The New Brunswick, New Jersey-based company posted revenue of $18.48 billion in the period, up 3.9 percent and well above Street forecasts for $17.89 billion.

Shares were up $2.14, or 1.7 percent, at $125.38 in afternoon trading after peaking earlier at an all-time high of $125.47.

Analyst Jeffrey Loo at S&P Capital Global Market Intelligence kept his”Buy” recommendation on J&J and raised his 12-month target price for its shares by $10, to $143. He wrote that he expects growth in consumer sales in the second half and is “encouraged by the improvement” in medical devices.

Credit Suisse analyst Vamil K. Divan wrote to investors that the “strong quarter” was driven by better-than-expected revenue in the prescription drugbusiness, “with almost all of the key growth drivers delivering,” and in the medical devices business, which is being reorganized due to slumping profits.

The company said the strong dollar, which reduces the value of products bought overseas in local currencies, lowered sales by 2.7 percent. Such unfavorable exchange rates have been hurting U.S.-based multinational companies for the last few years, but by much more until recently.

Johnson & Johnson raised its full-year earnings forecast to a range of $6.63 to $6.73 per share, up from its April forecast for $6.53 to $6.68 per share. It now expects revenue of $71.5 billion to $72.2 billion, up from $71.2 billion to $71.9 billion.

“Our second-quarter results have continued the momentum that began with our first quarter,” CEO Alex Gorsky told analysts during a conference call.

Sales of prescription drugs, J&J’s largest business, climbed 8.9 percent to $8.65 billion in the quarter, mostly due to a 13.2 percent jump in U.S. sales. Those increases were mainly driven by surging sales of newer medicines, including Imbruvica for blood cancer, type 2 diabetes pill Invokana, Darzalex for the bone marrow cancer multiple myeloma and heavily advertised Xarelto, for preventing heart attacks and strokes.

Combo diabetes pill Invokamet won U.S. approval during the quarter and three medicines were approved for sale in the European Union.

Sales of medical devices and diagnostics dipped nearly a percent to $6.41 billion, partly due to last year’s sale of the Cordis heart devices unit. Gorsky noted J&J saw increases around 3 percent in the latest quarter in hospital admissions and procedures, which boosts sales for that business and some of its medicines.

Sales of consumer health products dipped 1.8 percent to $3.42 billion, despite strong sales from pain relievers Tylenol and Motrin and skin care lines Aveeno and Neutrogena. On Monday, J&J closed a $3.3 billion acquisition of hair and personal products maker Vogue International LLC, and during the second quarter, it bought “dermocosmetics” maker NeoStrata Co. Inc.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE